Embecta, which recently completed its spin-off from Becton Dickinson, is forging ahead with its insulin injector-based business strategy, GLP-1s be damned. 

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Executives On The Move will be running to a monthly schedule from now, with this edition covering medtech's executive changes for April.

Becton Dickinson has formally completed the planned spin-off of its diabetes business within the timeframe it projected about a year ago. The new company, called embecta, is one of the largest producers of diabetes injection devices.